Pharmaxis Ltd (ASX:PXS, OTC:PMXSF)'s Gary Phillips speaks to Proactive following the news an Investigational New Drug application for a trial of PXS‐5505 in hepatocellular carcinoma (HCC) patients has been cleared by the FDA. The IND was submitted by the University of Rochester Medical Center following positive pre‐clinical results reported in August.
Pharmaxis receives approval for phase 2 study of its cancer drug in liver cancer
